Cefotetan Therapy for Gonococcal Urethritis and Cervicitis

Youssef, Rafik Z.; Murray, Maryann; Holmes, B; Mogabgab, William J.

doi:10.1097/00007435-199004000-00011

Cited by 3 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several other oral and parenterally administered drugs possess antigonococcal activity, thus being additional candidates for test standardization. Cefotetan, the subject of this study, was such a compound that has demonstrated clinical success against gonorrhea (7,11,20). These features are shared with cefoxitin, a similar cephamycin compound (2,12,17,21).…”

Section: U>40mentioning

confidence: 93%

“…Therapeutic failures were observed to occur among some P-lactamase-negative gonococci which were possibly strains with chromosomally mediated penicillin resistance (MIC of cefotetan for 50% of strains tested, 2 ,ug/ml). For the organism from one patient with a reported treatment failure, the cefotetan MIC was 8 ,ug/ml (20). Furthermore, therapy against some gonococci for which the cefotetan MICs were >2 ,ug/ml failed in another clinical trial (11).…”

Section: Methodsmentioning

confidence: 99%

“…All 30-jig cefotetan disk zones were .15 mm. Clinical failures with the clinical trial-recommended cefotetan doses (0.5 to 1 g) have been rare (7,11,20). Two reported clinical series (7, 20) rarely contained N. gonorrhoeae strains for which the cefotetan MICs were >4 p,g/ml.…”

Section: Methodsmentioning

confidence: 99%

“…Interpretive criteria are proposed for cefotetan based on in vitro data and in vivo considerations (7,8,12,16,18,20). A susceptible category has been defined (MIC, c2 ,ug/ml; zone diameter, -26 mm) that was similar to that of cefoxitin.…”

Section: U>40mentioning

confidence: 99%

“…Since cefotetan has superior pharmacokinetics compared with those of cefoxitin, probenicid is not required (16). Clinical success with single 500-mg or 1-g cefotetan regimens have been reported (7,11,20). In this report we summarize the development of cefotetan gonococcal susceptibility test interpretive criteria by using methods recommended by the National Committee for Clinical Laboratory Standards (NCCLS) and CDC (3,10,14,15).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan

et al. 1991

View full text Add to dashboard Cite

Cefotetan was tested in a multilaboratory study to standardize susceptibility testing criteria and quality control guidelines for Neisseria gonorrhoeae. Cefotetan was most active against penicillinase-producing and penicillin-susceptible strains (MIC for 50% of strains tested, 0.5 ,ug/ml) and was least active against the chromosomally resistant isolates (MIC for 50% of strains tested, 2 ,ug/ml). The recommended 30-,ug disk cefotetan interpretive criteria were as follows: susceptible at .26 mm (c2 rig/ml), intermediate at 20 to 25 mm (4 ,ug/ml), and resistant at l19 mm (.8 ,Lg/ml). Quality control guidelines for agar dilution and disk diffusion tests were established by using numerous GC agar lots, three cefotetan 30-,ug disk lots, two quality control organisms, and a volume of tests consistent with National Committee for Clinical Laboratory Standards M23-T guidelines.

show abstract

Section: U>40mentioning

confidence: 93%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: U>40mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan

et al. 1991

View full text Add to dashboard Cite

show abstract

Antibiotic use in the emergency department. IV: Single-dose therapy and parenteral-loading dose therapy

Hoang

Pollack

1996

The Journal of Emergency Medicine

View full text Add to dashboard Cite

Drugs of Choice for the Treatment of Uncomplicated Gonococcal Infections

Moran

Levine

1995

Clinical Infectious Diseases

171

124

View full text Add to dashboard Cite

Resistance of Neisseria gonorrhoeae to antimicrobial agents continues to spread and intensify. Choosing an antimicrobial regimen requires knowledge of the comparative efficacy of candidate regimens, as delineated in properly conducted clinical trials; their activity against N. gonorrhoeae in vitro; and their pharmacokinetics and toxicity. We tabulated the results of trials of single-dose antimicrobial therapy for uncomplicated gonococcal infection published after 1980. Thirty regimens comprising 21 antimicrobial drugs have been shown to be highly effective for rectal and urogenital infections; the agents involved are cefixime, cefodizime, cefotaxime, cefoxitin, ceftizoxime, ceftriaxone, cefuroxime, cefuroxime axetil, ciprofloxacin, fleroxacin, norfloxacin, ofloxacin, pefloxacin, temafloxacin, azithromycin, aztreonam, netilmicin, rifampin plus erythromycin stearate, sisomicin, and spectinomycin. Few regimens have been shown to be highly effective against pharyngeal infections. Among those antimicrobial agents available for the treatment of uncomplicated gonococcal infections in the United States, ceftriaxone (125 mg), cefixime (400 mg), ciprofloxacin (500 mg), and ofloxacin (400 mg) appear to offer the best balance of proven efficacy and safety.

show abstract

Cefotetan Therapy for Gonococcal Urethritis and Cervicitis

Cited by 3 publications

References 7 publications

Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan

Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan

Antibiotic use in the emergency department. IV: Single-dose therapy and parenteral-loading dose therapy

Drugs of Choice for the Treatment of Uncomplicated Gonococcal Infections

Contact Info

Product

Resources

About